Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ethmozine for ventricular premature complexes.

K Gear, F I Marcus, S K Huang

    The American Journal of Cardiology
    |April 15, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Toward the Discovery of New Elements: Production of Livermorium (Z=116) with ^{50}Ti.

    Physical review letters·2024
    Same author

    First Exploration of Monopole-Driven Shell Evolution above the N=126 Shell Closure: New Millisecond Isomers in ^{213}Tl and ^{215}Tl.

    Physical review letters·2024
    Same author

    Development of a reactor for the in situ monitoring of 2D materials growth on liquid metal catalysts, using synchrotron x-ray scattering, Raman spectroscopy, and optical microscopy.

    The Review of scientific instruments·2020
    Same author

    Tomography and imaging at the PSICHE beam line of the SOLEIL synchrotron.

    The Review of scientific instruments·2016
    Same author

    The In situ growth of Nanostructures on Surfaces (INS) endstation of the ESRF BM32 beamline: a combined UHV-CVD and MBE reactor for in situ X-ray scattering investigations of growing nanoparticles and semiconductor nanowires.

    Journal of synchrotron radiation·2015
    Same author

    Quantitative contrast-enhanced ultrasound of intraplaque neovascularization in patients with carotid atherosclerosis.

    Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2014
    Same journal

    Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

    The American journal of cardiology·2026
    Same journal

    ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

    The American journal of cardiology·2026
    Same journal

    Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

    The American journal of cardiology·2026
    Same journal

    Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

    The American journal of cardiology·2026
    Same journal

    Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

    The American journal of cardiology·2026
    Same journal

    Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

    The American journal of cardiology·2026
    See all related articles

    Ethmozine effectively suppressed frequent ventricular premature complexes (VPCs) in 50% of patients, including those unresponsive to other antiarrhythmic drugs. This study highlights ethmozine

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Frequent ventricular premature complexes (VPCs) pose a significant clinical challenge.
    • Many patients with VPCs are refractory to or intolerant of existing antiarrhythmic therapies.
    • Ethmozine is an antiarrhythmic drug with potential efficacy in selected patient populations.

    Purpose of the Study:

    • To evaluate the efficacy and clinical utility of ethmozine in suppressing frequent VPCs.
    • To assess the response to ethmozine in patients with a history of treatment failure or adverse reactions to other antiarrhythmic drugs.

    Main Methods:

    • Twenty patients with an average of over 30 VPCs per hour were enrolled.
    • Patients received ethmozine at 200-300 mg three times daily for up to 6 months.
    • Efficacy was assessed by reduction in VPC frequency, paired VPCs, and ventricular tachycardia (VT) events.

    Related Experiment Videos

    Main Results:

    • Eleven of 17 evaluable patients (65%) showed >75% reduction in VPC frequency.
    • Significant reductions in paired VPCs (11/16 patients, 68%) and VT events (11/13 patients, 84%) were observed.
    • Ethmozine was effective in 50% (10/20) of the selected patient population, with some adverse effects noted.

    Conclusions:

    • Ethmozine demonstrates efficacy and clinical usefulness for suppressing frequent VPCs in a selected group of patients.
    • The drug is particularly valuable for patients who have not responded to or experienced adverse reactions with other antiarrhythmic agents.
    • Further investigation may be warranted to optimize ethmozine use and manage potential side effects.